In a patient with recurrent headaches, intense hunger, fasting and post‑prandial glucose never below 80 mg/dL, and a continuous glucose monitor showing no hypoglycemia, can insulinoma be ruled out?

No, insulinoma cannot be ruled out based on CGM alone showing no hypoglycemia below 80 mg/dL

The absence of documented hypoglycemia on continuous glucose monitoring does not exclude insulinoma, and this patient requires formal biochemical testing with a supervised 72-hour fast to definitively rule out this diagnosis.

Why CGM is Insufficient for Excluding Insulinoma

The Endocrine Society guidelines define biochemically significant hypoglycemia as plasma glucose less than 55 mg/dL (3.0 mmol/liter), not 80 mg/dL 1. Your patient's CGM showing glucose never below 80 mg/dL does not reach the diagnostic threshold where insulinoma would be expected to manifest. However, this creates a diagnostic dilemma rather than providing reassurance.

Critical Diagnostic Pitfalls

Several important caveats make CGM unreliable for excluding insulinoma:

• CGM accuracy limitations: CGM devices may not capture brief, severe hypoglycemic episodes, particularly nocturnal events or rapid glucose fluctuations
• Timing of monitoring: The patient may not have been monitored during the specific circumstances that provoke hypoglycemia (prolonged fasting, specific meal patterns)
• Insulinomas can present with postprandial hypoglycemia: While classically causing fasting hypoglycemia, 9% of insulinoma patients present with only postprandial symptoms 2
• Diagnostic delays are common: Cases exist with 19-year delays between initial presentation and diagnosis when early testing was negative 3

The Algorithmic Approach to This Patient

Step 1: Recognize the Clinical Syndrome

This patient has Whipple's triad components:

• Symptoms consistent with hypoglycemia (headaches, intense hunger)
• However, documented glucose levels don't meet the <55 mg/dL threshold yet

Step 2: Proceed with Supervised 72-Hour Fast

The gold standard remains the supervised 72-hour fasting test, which should be performed even when outpatient monitoring appears negative 1. During this test, measure:

• Plasma glucose
• Insulin (diagnostic threshold ≥3.0 μU/mL, though ≥6 μU/mL is more specific)
• C-peptide (≥0.6 ng/mL indicates endogenous insulin)
• Proinsulin (≥5.0 pmol/liter)
• β-hydroxybutyrate (≤2.7 mmol/liter suggests insulin-mediated hypoglycemia)
• Screen for oral hypoglycemic agents

Step 3: Consider Repeat Testing if Initial Test is Negative

Critical point: In one series, a patient with insulinoma had an initially negative 72-hour fast that became positive after 2-year follow-up 2. If clinical suspicion remains high despite negative testing, repeat the fast test.

Step 4: Recognize Atypical Presentations

Be aware that:

• Low insulin levels don't exclude insulinoma: Case reports document insulinomas with inappropriately low insulin but elevated C-peptide 4
• Pre-existing diabetes or impaired glucose tolerance occurs in 21% of insulinoma patients 2
• Symptoms may be exclusively postprandial in some cases 2

Why This Patient Needs Further Workup

The combination of:

• Recurrent symptoms suggestive of hypoglycemia (headaches, intense hunger)
• No documented biochemical hypoglycemia <55 mg/dL
• CGM showing glucose never below 80 mg/dL

...creates three possibilities:

1. The symptoms are not hypoglycemia-related (most likely if formal testing is negative)
2. Insulinoma exists but hasn't been captured yet (requires supervised fast)
3. Another cause of hypoglycemia exists (requires the differential workup per guidelines)

The only way to definitively exclude insulinoma is through supervised biochemical testing during symptomatic episodes or provoked hypoglycemia via the 72-hour fast 1. The supervised setting ensures accurate plasma glucose measurement (not interstitial glucose from CGM) and simultaneous insulin/C-peptide/proinsulin levels at the critical moment of hypoglycemia.

Bottom Line

Proceed with supervised 72-hour fasting test with complete biochemical panel. If negative and symptoms persist, consider repeat testing after interval follow-up, as insulinomas can remain occult for years 3. CGM data showing no hypoglycemia below 80 mg/dL provides false reassurance and should not deter appropriate diagnostic evaluation when clinical suspicion exists.